[PMID]: | 27483712 |
[Au] Autor: | Carauleanu A; Socolov R; Rugina V; Gabia O; Carauleanu DM; Lupascu IA; Socolov D |
[Ti] Título: | COMPARISONS BETWEEN THE NON-PROLIFERATIVE AND PROLIFERATIVE THERAPY IN FIBROCYSTIC MASTOSIS. |
[So] Source: | Rev Med Chir Soc Med Nat Iasi;120(2):321-7, 2016 Apr-Jun. |
[Is] ISSN: | 0048-7848 |
[Cp] País de publicação: | Romania |
[La] Idioma: | eng |
[Ab] Resumo: | AIM: Fibrocystic mastosis (FCM) is the most frequent benign breast lesion. Most treatments for fibrocystic mastosis are: hormonl, with beneficial results and non-hormonal, with fluctuating results. MATERIAL AND METHODS: A number of 210 cases were studied, which were divided into 7 groups. The study lasted for 9 months and it was carried out on the basis of a personal examination sheet. The following were monitored: age groups, mastodynia, reducing breast nodules, a significant reduction in the volume of the mastosic cysts, reducion of the fibrous tissue, medication tolerance. RESULTS: Mastodynia has declined by 90% in the cases treated with Tamoxifen and Danazol, by 70% in the case of Lynestrenol and Bromocriptine, by 50% in the 15 patients who were given Utrogestan. Knowing the advantages and disadvantages of drugs (contraindications, side effects), age category, breast pain reduction, antiproliferative activity, tolerability, relapse allow us to assess the benefit-risk. Even in those circumstances that remained incompletely clarified for objective reasons, related to the inaccurate/incorrect reporting by the patients, there is a significant difference (p < 0.05) between the frequency of relapses following the treatment with Tamoxifen and the other categories of drugs who were administered. CONCLUSIONS: Our study shows that in the groups that were administered Logest, Utrogestan and Bromocriptine, only antalgic effects were achieved (disappearance or only decrease of mastodynia) and no anti-proliferative effects were obtained. Basically, hormone treatment should be made based on a histopathological examination. |
[Mh] Termos MeSH primário: |
Antineoplásicos Hormonais/uso terapêutico Anticoncepcionais Orais Sintéticos/uso terapêutico Danazol/uso terapêutico Doença da Mama Fibrocística/tratamento farmacológico Antagonistas de Hormônios/uso terapêutico Tamoxifeno/uso terapêutico
|
[Mh] Termos MeSH secundário: |
Bromocriptina/uso terapêutico Quimioterapia Combinada Feminino Doença da Mama Fibrocística/patologia Seguimentos Seres Humanos Linestrenol/uso terapêutico Dor/tratamento farmacológico Estudos Retrospectivos Medição de Risco Resultado do Tratamento
|
[Pt] Tipo de publicação: | COMPARATIVE STUDY; JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (Antineoplastic Agents, Hormonal); 0 (Contraceptives, Oral, Synthetic); 0 (Hormone Antagonists); 094ZI81Y45 (Tamoxifen); 3A64E3G5ZO (Bromocriptine); N29QWW3BUO (Danazol); N2Z8ALG4U5 (Lynestrenol) |
[Em] Mês de entrada: | 1610 |
[Cu] Atualização por classe: | 161230 |
[Lr] Data última revisão:
| 161230 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 160804 |
[St] Status: | MEDLINE |
|
|